医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

World’s First Phase III Clinical Trial of COVID-19 Inactivated Vaccine Begins in UAE

2020年07月17日 PM04:00
このエントリーをはてなブックマークに追加


 

ABU DHABI, United Arab Emirates

The first WHO enlisted global clinical Phase III trial of Sinopharm CNBG’s inactivated vaccine to combat COVID-19 has started in Abu Dhabi, inspired by the UAE Leadership’s commitment to overcome the pandemic through a global collaborative effort.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200717005085/en/

H.E. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of Department of Health, Abu Dhabi, being administered the world’s first clinical Phase III trial of inactivated vaccine to combat COVID-19 (Photo - AETOSWire).

H.E. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of Department of Health, Abu Dhabi, being administered the world’s first clinical Phase III trial of inactivated vaccine to combat COVID-19 (Photo – AETOSWire).

H.E. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of the Department of Health, Abu Dhabi, was the first in the world to commence the trial of a Phase III inactivated vaccine for COVID-19 that is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare and Sinopharm CNBG, the world’s sixth largest vaccine manufacturer.

The UAE was selected to conduct the trials as the nation is home to over 200 nationalities, allowing for robust research across multiple ethnicities and increasing its feasibility for global application. They are being operated by Abu Dhabi Health Services (SEHA) who are providing clinical facilities.

UAE Health Authorities have issued a permit for up to 15,000 volunteers to participate and G42 Healthcare and SEHA are working towards achieving a minimum of 5,000 participants for the trials being supervised by the Department of Health Abu Dhabi and SEHA following international guidelines stipulated by WHO and USFDA.

Chairperson of the UAE National COVID-19 Clinical Management Committee Dr. Nawal Ahmed Alkaabi said: “Our participation in this trial enables us to make a major contribution in the global fight to combat the COVID-19 pandemic. We are proud to facilitate the testing process that if successful leads to the manufacture of a vaccine.”

It follows successful phase I and II trials by Sinopharm in China, resulting in 100% of volunteers generating antibodies.

G42 Healthcare CEO Ashish Koshy said: “We are enormously proud to partner with Sinopharm CNBG in this groundbreaking phase III clinical trial. Using our AI solutions, super-computer, advanced diagnostics solutions for COVID-19, and G42 Healthcare will be responsible for running clinical operations for these trials.”

Jingjin Zhu, President, Biological products, Sinopharm CNBG added: “The UAE is a nation of innovation and tolerance, home to individuals from every part of the world and ethnic background. We will work closely with our partner G42 Healthcare, with the support of the Abu Dhabi health authorities to complete these clinical trials successfully and make this vaccine available to people in need worldwide.”

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20200717005085/en/

CONTACT

Tasneem Riyaz

g42@apcoworldwide.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease